MAP2K1 and neoplasm: Histopathological and immunohistochemical analyses confirmed that these organoids recapitulated the architectural and molecular features of the original tumors, including expression of established tumor markers (EpCAM, CA125, PAX8) and potential therapeutic targets (HER2, MEK1/2, Cyclin E1).